

FORM 10

NOTICE OF PROPOSED SIGNIFICANT TRANSACTION (not involving an issuance or potential issuance of a listed security)¹

Name of Listed Issuer: **Abattis Bioceuticals Corp.** (the “Issuer”).

Trading Symbol: **ATT**

Issued and Outstanding Securities of the Issuer Prior to Transaction: **477,804,139
Common Shares**

Date of News Release Fully Disclosing the Transaction: **April 2, 2019**

1. Transaction

1. Provide details of the transaction including the date, description and location of assets, if applicable, parties to and type of agreement (eg: sale, option, license, contract for Investor Relations Activities etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

The share purchase agreement was entered into on March 27, 2019 (the “Agreement”) between 1185277 B.C. Ltd., a wholly-owned subsidiary of the Issuer (the “Acquisition Subsidiary”); and Catalyst Investment Capital Corp. (“Catalyst”). Catalyst is a non-related party to the Issuer.

The Agreement provides for the acquisition by the Acquisition Subsidiary of 100% of Pro Natura BV’s outstanding shares from Catalyst in exchange for the payment of €6,684,200 to Catalyst, which will be paid as follows: (i) €2,000,000 on closing; (ii) €2,220,000 one year following closing; and (iii) €2,464,200 two years following closing. The Acquisition Subsidiary has also agreed to pay Catalyst (i) a €5,000,000 milestone payment within two years of the Issuer’s CBD products being launched through Pro Natura BV’s sales and (ii) a €4,000,000 milestone payment within two years of launch of sales of the Issuer’s proprietary product, Comfort, through Pro Natura BV’s sales channels. The Acquisition Subsidiary’s obligation to make these milestone payments will expire within three years from closing of the Agreement.

¹ If the transaction involved the issuance of securities, other than debt securities that are not convertible into listed securities, use Form 9.

2. Provide the following information in relation to the total consideration for the transaction (including details of all cash, non-convertible debt securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: **CAD \$10,093,810.42 (€6,684,200), based on the CAD/EUR exchange rate of 0.6622 on March 27, 2019**
 - (b) Cash: **€6,684,200**
 - (c) Other: **N/A**
 - (d) Work commitments: **N/A**
3. State how the purchase or sale price and the terms of any agreement were determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). **The purchase price was based on market value comparables, a third party valuation respecting Pro Natura BV and arm's length negotiations between the principals of Pro Natura BV and Catalyst and management of the Issuer.**
4. Provide details of any appraisal or valuation of the subject of the transaction known to management of the Issuer: **N/A**
5. If the transaction is an acquisition, details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: **N/A**
6. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the transaction (including warrants, options, etc.): **N/A**
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the transaction (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): **N/A**
 - (b) Cash: **N/A**
 - (c) Other: **N/A**
7. State whether the vendor, sales agent, broker or other person receiving compensation in connection with the transaction is a Related Person or has any other relationship with the Issuer and provide details of the relationship. **N/A**

8. If applicable, indicate whether the transaction is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. **N/A**

2. Development

Provide details of the development. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: **N/A**

[The remainder of this page is intentionally left blank.]

3. Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the knowledge of the Issuer, at the time an agreement in principle was reached, no party to the transaction had knowledge of any undisclosed material information relating to the Issuer, other than in relation to the transaction.
3. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
5. All of the information in this Form 10 Notice of Proposed Significant Transaction is true.

Dated April 3, 2019.

Rob Abenante
Name of Director or Senior
Officer

/s/ Rob Abenante
Signature

Director and CEO
Official Capacity